Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Innocan Pharma Corp (CSE: INNO ) 0.2500 +0.0150 (+6.38%) Streaming Delayed Price Updated: 9:40 AM EDT, Jul 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 500 Open 0.2350 Bid (Size) 0.2350 (500) Ask (Size) 0.2500 (149,500) Prev. Close 0.2350 Today's Range 0.2500 - 0.2500 52wk Range 0.1800 - 0.5200 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News CBD-Focused Innocan Pharma Achieves 4X Revenue Growth In Q1, Hits $6.8M Mark May 28, 2024 Innocan Pharma's Q1 2024 revenue surged 334% to $6.8M, driven by strong sales growth from BI Sky Global. Read about financial performance. Via Benzinga This Pharma Co. Kicks Off FDA Approval Process For CBD-Based Treatment Of Chronic Pain April 23, 2024 Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced on Monday that it has submitted its letter of application for a Pre-IND meeting with the U.S. Food and Drug Administration... Via Benzinga Exposures Product Safety Performance YTD -19.35% -19.35% 1 Month +2.04% +2.04% 3 Month -9.09% -9.09% 6 Month -18.03% -18.03% 1 Year +21.95% +21.95% More News Read More 534% Revenue Surge Unveiled By Israeli CBD-Focused Pharma Company, Exceeding Expectations April 02, 2024 Via Benzinga CBD-Focused Pharma Co. Innocan Reveals 433% YoY Increase In 2023 Revenue As It Pursues FDA Approval February 13, 2024 Via Benzinga Exposures Product Safety Key Leadership Changes In Cannabis You Should Know About As We Head Into 2024 December 22, 2023 Via Benzinga Topics Cannabis Exposures Cannabis More Cannabis Funding For FDA And Product Expansion: How This Pharma Tech Company Is Doing It October 23, 2023 Via Benzinga Topics Cannabis Exposures Cannabis Product Safety CBD-Focused Pharma Co. Seeks Funding To Revolutionize Healthcare September 21, 2023 Via Benzinga Innocan Pharma's Q2 2023 Reports Gross Profit Growth Driven By Robust Subsidiary Sales August 28, 2023 Via Benzinga Industry Update: Innocan Pharma Accelerates Commercialization in Europe Following Impressive Revenue Growth May 03, 2023 Via AB Newswire Topics Intellectual Property Exposures Intellectual Property Innovative Delivery Systems Create Unique Opportunities in the Billion-Dollar Pain Market (CSE: INNO) November 14, 2022 Via AB Newswire Topics Cannabis Exposures Cannabis Innocan Pharma Provides an Operational Update September 21, 2022 Via Newsfile Topics Intellectual Property Exposures Intellectual Property Innocan Pharma Reports Another Successful Result from a Pre-Clinical Study on a Dog Suffering from Refractory (Drug-Resistant) Epilepsy Following LPT Treatment September 09, 2022 Via Newsfile Innocan Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022 September 06, 2022 Via Newsfile Innocan Pharma's CBD-Loaded Liposome Platform Technology Demonstrates a Prolonged Release of CBD in Large Animals September 03, 2021 Via Newsfile Topics Intellectual Property Supply Chain Exposures COVID-19 Intellectual Property Supply Chain Innocan Pharma Received Proceeds of CAD $8.2M from the Exercise of Warrants since January 1, 2021 August 27, 2021 Via Newsfile Topics Supply Chain Exposures COVID-19 Supply Chain Innocan Exercises Option to Enter into a Research and License Agreement with Ramot the Commercial company of the Tel Aviv University August 18, 2021 Via Newsfile Topics Supply Chain Exposures COVID-19 Supply Chain Innocan Engages Ayurcann Inc. to Manufacture and Distribute Innocan's CBD Topicals in Canada August 11, 2021 Via Newsfile Topics Supply Chain Exposures COVID-19 Supply Chain Innocan Pharma Updates its Progress in the Pre-Clinical Studies of its CBD-Loaded Liposome Platform (LPT) August 03, 2021 Via Newsfile Topics Intellectual Property Supply Chain Exposures COVID-19 Intellectual Property Supply Chain Innocan Pharma Announces the Filing of a Patent Application for the Treatment and Prevention of Hair Loss July 28, 2021 Via Newsfile Topics Intellectual Property Supply Chain Exposures COVID-19 Intellectual Property Supply Chain Former Israeli Minister of Science and Technology and Highly Influential Venture Capitalist to Join Innocan Pharma's Advisory Committee July 14, 2021 Via Newsfile Topics Artificial Intelligence Supply Chain Exposures Artificial Intelligence COVID-19 Supply Chain Innocan Pharma Announces Filing of International Patent Application for Topical Treatment for Diabetic Symptoms July 09, 2021 Via Newsfile Topics Intellectual Property Supply Chain Exposures COVID-19 Intellectual Property Supply Chain Innocan Pharma and Health Investment Group S.A. Sign Exclusive Distribution Agreement for Poland July 01, 2021 Via Newsfile Topics Economy Supply Chain Exposures COVID-19 Economy Supply Chain Innocan Pharma's CBD Integrated Anti-Aging Sleeping Mask Demonstrates a Reduction of the Appearance of Wrinkles by up to 28.8% in 4 Weeks of Clinical Study June 24, 2021 Via Newsfile Topics Supply Chain Exposures COVID-19 Supply Chain Clinical Study Validates Innocan Pharma's SHIR(R) CBD Eye Serum as an Anti-Puffiness Solution June 16, 2021 Via Newsfile Topics Supply Chain Exposures COVID-19 Supply Chain Innocan Pharma Announces Patent Application for Novel Cannabis-Based Vaginal Moisturizer and Lubricant Treatment June 14, 2021 Via Newsfile Topics Intellectual Property Supply Chain Exposures COVID-19 Intellectual Property Supply Chain Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
